Cybrexa Therapeutics Completes $25M Series B Financing

11 Mar, 2021

Cybrexa Therapeutics Completes $25M Series B Financing
Photo by Joel Filipe on Unsplash

– Cybrexa Therapeutics from New Haven develops a new class of therapeutics through its alphalex™ Peptide Drug Conjugate (PDC) tumor targeting platform.
– The company completed its $25m Series B financing.
– Backers included HighCape Capital and new investor Elm Street Ventures.
– The new investment will be aimed at planned advancement of its lead candidate CBX-12 (alphalex™-exatecan) into the clinic.

Biotechnology North America Pharmaceutical Therapeutics
Crunchbase icon

Content report

The following text will be sent to our editors: